关注
Daniel Weiner
Daniel Weiner
Adjunct Professor, UNC & member BoD Simulations Plus
在 email.unc.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Pharmacokinetic and pharmacodynamic data analysis: concepts and applications
J Gabrielsson, D Weiner
CRC press, 2001
13642001
Non-compartmental analysis
J Gabrielsson, D Weiner
Computational Toxicology: Volume I, 377-389, 2012
3172012
Cardiovascular Properties of a New Cardiotonic Agent: MDL 17,043 (1, 3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2: H:-imidazol-2-one)
RC Dage, LE Roebel, CP Hsieh, DL Weiner, JK Woodward
Journal of Cardiovascular Pharmacology 4 (3), 500-508, 1982
1271982
Precision dosing priority criteria: drug, disease, and patient population variables
RJ Tyson, CC Park, JR Powell, JH Patterson, D Weiner, PB Watkins, ...
Frontiers in pharmacology 11, 420, 2020
742020
Bioavailability of terfenadine in man
RA Okerholm, DL Weiner, RH Hook, BJ Walker, GA Leeson, ...
Biopharmaceutics & drug disposition 2 (2), 185-190, 1981
731981
Apparatus and methods for control of intravenous sedation
DL Weiner
US Patent 6,165,151, 2000
432000
Drug Dosing Recommendations for All Patients: A Roadmap for Change
D Powell, J., Cook, J., Wang, Y., Peck, R., Weiner
Clinical Pharmacology & Therapeutics, 2020
39*2020
Design and analysis of bioavailability studies
DL Weiner
Statistics in the pharmaceutical industry, 205-229, 1981
321981
Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses
BD Hamamoto‐Hardman, EP Steffey, D Weiner, DS McKemie, P Kass, ...
Journal of veterinary pharmacology and therapeutics 42 (4), 401-410, 2019
312019
The future of the pharmaceutical sciences and graduate education: Recommendations from the AACP Graduate Education Special Interest Group
S Wu-Pong, J Gobburu, S O’Barr, K Shah, J Huber, D Weiner
American Journal of Pharmaceutical Education 77 (4), S2, 2013
312013
Antihypertensive and adrenergic receptor blocking properties of the enantiomers of medroxalol
HC Cheng, OK Reavis Jr, JM Grisar, GP Claxton, DL Weiner, ...
Life Sciences 27 (25-26), 2529-2534, 1980
251980
Pattern recognition in pharmacokinetic data analysis
J Gabrielsson, B Meibohm, D Weiner
The AAPS journal 18, 47-63, 2016
222016
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes
SJ Balevic, D Weiner, MEB Clowse, AM Eudy, AR Maharaj, CP Hornik, ...
Lupus Science & Medicine 9 (1), e000602, 2022
182022
Rivaroxaban precision dosing strategy for real‐world atrial fibrillation patients
R Konicki, D Weiner, J Herbert Patterson, D Gonzalez, A Kashuba, ...
Clinical and Translational Science 13 (4), 777-784, 2020
172020
Pharmacokinetic and Pharmacodynamic Analysis: Concepts and Applications, Swedish Pharmaceutical Society
J Gabrielsson, D Weiner
Swedish Pharmaceutical Press, Stockholm, Sweden 1997, 1997
141997
Pharmacokinetic and pharmacodynamic data analysis
J Gabrielson, D Weiner
Concept and Application, 1994
131994
A simulation study of parameter estimation in the one and two compartment models
PM Laskarzewski, DL Weiner, L Ott
Journal of Pharmacokinetics and Biopharmaceutics 10 (3), 317-334, 1982
131982
Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to …
HK Knych, D Weiner, RM Arthur, R Baden, DS McKemie, PH Kass
Drug testing and analysis 12 (8), 1087-1101, 2020
122020
Modeling strategies
J Gabrielsson, D Weiner
Pharmacokinetic and Pharmacodynamic Analysis: Concepts and Applications, 460, 2000
122000
The pharmacokinetics of a new cardiotonic agent, MDL 19205, 4-ethyl-1, 3-dihydro-5-(4-pyridinyl)-2H-imidazol-2-one (abstr)
RA Okerholm, FJ Keeley, DL Weiner, RB Spangenberg
Fed Proc 42, 1131, 1983
101983
系统目前无法执行此操作,请稍后再试。
文章 1–20